Preparation of crystals for characterizing the Grb7 SH2 domain before and after complex formation with a bicyclic peptide antagonist

The SH2 domain of Grb7 has been crystallized in the apo form and in complex with a bicyclic peptide ligand. These structures will assist the development of potent Grb7 inhibitors as breast cancer therapeutics.